CD28H/IGPR-1 hFc Chimera, Human
CD28H/IGPR-1 HFc Chimera, Human

Immobilized Human B7-H7, His Tag at 5 μg/ml (100 μL/well) on the plate. Dose response curve for CD28H/IGPR-1 hFc Chimera, Human, hFc Tag with the EC50 of 63.4 ng/ml determined by ELISA.

CD28H/IGPR-1 HFc Chimera, Human

The purity of CD28H/IGPR-1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

CD28H/IGPR-1 HFc Chimera, Human

CD28H/IGPR-1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CD28H/IGPR-1 hFc Chimera, Human

CD28H is constitutively expressed on all naive T cells. Repetitive antigenic exposure, however, induces a complete loss of CD28H on many T cells, and CD28H negative T cells have a phenotype of terminal differentiation and senescence. After extensive screening in a receptor array, a B7-like molecule, B7 homologue 5 (B7-H5), was identified as a specific ligand for CD28H.
Z04184
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CD28H/IGPR-1 (Leu23-Gly150)
Accession # Q96BF3-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Human B7­H7, His Tag at 5μg/ml (100μl/well) on the plate can bind CD28H/IGPR-1 hFc Chimera, Human. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 40.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • CD28H/IGPR-1 HFc Chimera, Human
    • CD28H/IGPR-1 HFc Chimera, Human

    Immobilized Human B7-H7, His Tag at 5 μg/ml (100 μL/well) on the plate. Dose response curve for CD28H/IGPR-1 hFc Chimera, Human, hFc Tag with the EC50 of 63.4 ng/ml determined by ELISA.

  • CD28H/IGPR-1 HFc Chimera, Human
    • CD28H/IGPR-1 HFc Chimera, Human

    The purity of CD28H/IGPR-1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • CD28H/IGPR-1 HFc Chimera, Human
    • CD28H/IGPR-1 HFc Chimera, Human

    CD28H/IGPR-1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background CD28H is constitutively expressed on all naive T cells. Repetitive antigenic exposure, however, induces a complete loss of CD28H on many T cells, and CD28H negative T cells have a phenotype of terminal differentiation and senescence. After extensive screening in a receptor array, a B7-like molecule, B7 homologue 5 (B7-H5), was identified as a specific ligand for CD28H.
Synonyms TMIGD2; IGPR1; IGPR-1; CD28H; TPC1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.